Prostigmin Bromide Alternatives Compared
| Prostigmin Bromide (neostigmine) | Ravulizumab | Rystiggo (rozanolixizumab) |
|
|---|
| Prostigmin Bromide (neostigmine) | Ravulizumab | Rystiggo (rozanolixizumab) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Myasthenia Gravis, Urinary Retention. Prostigmin Bromide may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myasthenia Gravis, Paroxysmal Nocturnal Hemoglobinuria, Neuromyelitis Optica Spectrum Disorder, Hemolytic Uremic Syndrome. Ravulizumab may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Myasthenia Gravis. Rystiggo may also be used for purposes not listed in this medication guide. |
Related suggestions Myasthenia Gravis
|
|||||||
| More about Prostigmin Bromide (neostigmine) | More about Ravulizumab | More about Rystiggo (rozanolixizumab) | ||||||||
| Ratings & Reviews | ||||||||||
|
Prostigmin Bromide has an average rating of 10.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Ravulizumab has an average rating of 9.6 out of 10 from a total of 7 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Rystiggo has an average rating of 8.0 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
| Lower cost generic approved |
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Rystiggo prices |
||||||||
| Dosage Forms Available | ||||||||||
|
N/A |
N/A |
|
||||||||
| Brand Names | ||||||||||
| Other neostigmine brands include: Bloxiverz | Ultomiris |
N/A |
||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
2 hours |
1192.8 hours |
N/A |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 109 drugs are known to interact with Prostigmin Bromide:
|
A total of 78 drugs are known to interact with Ravulizumab:
|
A total of 282 drugs are known to interact with Rystiggo:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
N/A |
N/A |
June 26, 2023 |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
| Professional Resources | ||||||||||
|
N/A |
||||||||||
| Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.